Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome

Liver Transpl. 2018 Feb;24(2):171-181. doi: 10.1002/lt.24979.

Abstract

Common variable immunodeficiency (CVID) is the most common form of primary immunodeficiency characterized by antibody deficiency, recurrent bacterial infections, and autoimmunity. Advanced chronic liver disease occurs in a subset of patients with CVID and manifests with various histological features, such as nodular regenerative hyperplasia, inflammation, fibrosis, and cholangiopathy. We present a case series characterizing the outcomes in adult patients transplanted for primary CVID-related liver disease. We discuss the unique transplantation challenges faced in this primary immunodeficiency group including susceptibility to infections and early disease recurrence. There is a statistically significant decrease in 3-year and 5-year survival after liver transplantation in those with CVID-related liver disease (55% at 3 and 5 years) compared with all-comers (89% at 3 years, 81% at 5 years), prompting a need for discussion of suitability of transplantation in this group of patients as well as methods for reducing posttransplantation risk such as scrupulous search for infectious agents and reduction of immunosuppression. Liver Transplantation 24 171-181 2018 AASLD.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chronic Disease
  • Common Variable Immunodeficiency / complications
  • Common Variable Immunodeficiency / diagnosis
  • Common Variable Immunodeficiency / immunology*
  • Fatal Outcome
  • Female
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects
  • Liver Diseases / diagnosis
  • Liver Diseases / immunology
  • Liver Diseases / surgery*
  • Liver Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Recurrence
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Immunosuppressive Agents